摘要:
A compound of the formula and physiologically acceptable salts and or N-oxides thereof wherein, X1 is N or CR3; X2 is N or CR4; X3 is N or CR5; X4 is N or CR6. with the proviso that at least one but not more than two of X1, X2, X3 and X4 represents N. R1 is a 5-, or 6-membered heterocyclic group selected from group a, b, c or d wherein X5 is a group selected from N or CR7 and X6 is a group selected from O, S or NR8; X7 and X8 which may be the same or different is a group selected from N or CR9; X9 is a group selected from O, S or NR8 and X10 is N or CR10; X11, X12 and X13 may be the same or different and selected from a group N or CR11; processes for their preparation, pharmaceutical compositions containing them and their use in medicine.
摘要翻译:下式的化合物及其生理上可接受的盐和/或其N-氧化物,其中X 1是N或CR 3; X 2是N或CR 4; X 3是N或CR 5; X 4是N或CR 6。 条件是X 1,X 2,X 3和X 4中的至少一个但不多于两个, SUB>表示N. R 1是选自a,b,c或d的5-或6-元杂环基,其中X 5是选自 N或CR 7和X 6是选自O,S或NR 8的基团; 可以相同或不同的是选自N或CR 9的基团;其中X 1和X 3可以相同或不同。 X 9是选自O,S或NR 8和X 10的基团是N或CR 10; X 11,X 12和X 13可以相同或不同,选自基团N或CR 13, 11 SUB> 其制备方法,含有它们的药物组合物及其在医药中的用途。
摘要:
The present invention relates to novel fused thiazole derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
摘要:
Control of supplying power to a storage device is performed based on carbon emission strength or a power rate.A battery center 13 that constitutes a storage device 11 performs radio communication with a gateway 4 and is controlled by the gateway 4. The gateway 4 collects a measured value of power consumed by electric appliances in a home and obtains the carbon emission strength in real time. A solar panel 9 is provided and a battery of the storage device 11 is charged with an output of the solar panel. The battery is also charged with direct current power obtained from power from outside. The power is stored in the storage device 11 based on the carbon emission strength by charging control.
摘要:
The present invention relates to novel benzazepine derivatives of structure (I) having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders. These compounds act as histamine H3 antagonists.
摘要:
A compound of the formula and physiologically acceptable salts and or N-oxides thereof wherein, X1 is N or CR3; X2 is N or CR4; X3 is N or CR5; X4 is N or CR6. with the proviso that at least one but not more than two of X1, X2, X3 and X4 represents N. R1 is a 5-, or 6-membered heterocyclic group selected from group a, b, c or d wherein X5 is a group selected from N or CR7 and X6 is a group selected from O, S or NR8; X7 and X8 which may be the same or different is a group selected from N or CR9; X9 is a group selected from O, S or NR8 and X10 is N or CR10; X11, X12 and X13 may be the same or different and selected from a group N or CR11; processes for their preparation, pharmaceutical compositions containing them and their use in medicine.
摘要翻译:下式的化合物及其生理上可接受的盐和/或其N-氧化物,其中X 1是N或CR 3; X 2是N或CR 4; X 3是N或CR 5; X 4是N或CR 6。 条件是X 1,X 2,X 3和X 4中的至少一个但不多于两个, SUB>表示N. R 1是选自a,b,c或d的5-或6-元杂环基,其中X 5是选自 N或CR 7和X 6是选自O,S或NR 8的基团; X 7和X 8可以相同或不同,是选自N或CR 9的基团。 X 9是选自O,S或NR 8和X 10的基团是N或CR 10; X 11,X 12和X 13可以相同或不同,并且选自N或C 11 SUB >; 其制备方法,含有它们的药物组合物及其在医药中的用途。